Verici Dx PLC First European Clinical Trial Site Initiated (7402F)
20 Julio 2021 - 01:00AM
UK Regulatory
TIDMVRCI
RNS Number : 7402F
Verici Dx PLC
20 July 2021
Verici Dx plc
("Verici Dx" or the "Company")
Verici expands its clinical trial by opening first site in
Europe
Multi-centre validation trial for leading products on track for
completion by the end of the year
including participation from European sites
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces that it has initiated
its first European clinical validation trial site with Prof.
Gaetano La Manna, Director of the Specialization School in
Nephrology and the Dialysis and Transplant Unit, at the Sant'Orsola
Polyclinic Hospital in Bologna, Italy.
The trial is a global, non-randomised, observational study for
the clinical validation of Verici Dx's lead products, Clarava (TM)
to predict risk of early acute rejection in the first six months
post-transplant and Tuteva (TM) for the diagnosis of acute
cell-mediated rejection, and over the longer term, for the
validation of the Company's fibrosis test, now called
Protega(TM).
Prof. Gaetano La Manna is the Director of the Nephrology,
Dialysis and Transplantation Unit at the IRCCS-Sant'Orsola
Polyclinic Hospital; he is Director of the School of Specialization
in Nephrology of the University of Bologna; Full Professor of
Nephrology at the University of Bologna, as well as Deputy
Coordinator and member of the Board of Professors of the Research
Doctorate in Cardio-Nephro-Thoracic Sciences. Prof. La Manna holds
a PhD in Nephrology and Post-Doctorate in Medical Sciences. He has
extensive experience in both clinical and experimental nephrology,
dialysis and kidney transplantation, and also in the medical
management of kidney transplant and its complications. The Kidney
Transplant Center of the University of Bologna, inside the IRCCS
Sant'Orsola Polyclinic Hospital, is one of the most important in
Europe for number, quality and complexity of transplants, with more
than 3,000 to its credit, including donation after brainstem death
(DBD), donation after circulatory death (DCD), marginal donor,
double transplants, ABO incompatible, hyperimmunized patients,
combined kidney-liver, kidney-heart transplants and other special
programs.
Angela Rose, Senior Director of Clinical Trial Operations of
Verici Dx, said:
"The team has worked incredibly hard on this project, from
designing and developing the approach to implementing the trial. In
our effort to expand our clinical development and validation beyond
North America, we are pleased to be working with Prof. Gaetano La
Manna, a highly respected and experienced primary investigator, to
lead our trial in Bologna, Italy. The diversification of our
patient sample is a strategically important initiative for Verici,
as we seek to leverage our clinical expertise and demonstrate our
commitment to the development of globally validated transplant
diagnostics."
Verici Dx announced the collaboration with three leading US
centres for clinical validation trial of its lead products in March
2021 and has subsequently opened 2 more US centres. Enrolment is on
target for completion of the Clarava(TM) and Tuteva(TM) validation
study by the end of 2021. Data is expected to be published as soon
as practicably possible in 2022.
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser Tel: 020 7496 3000
& Broker)
Aubrey Powell / Justin McKeegan / Tom
Salvesen
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748 651 727
About Verici Dx plc www.vericidx.com
Verici Dx is developing and commercialising tests to understand
how a patient will and is responding to organ transplant, with an
initial focus on kidney transplants. The body's own immune system
poses a threat to a successful transplant or graft. Patients'
immune systems differ in how they respond to the presence of the
transplanted organ, characterising this response is called immune
phenotyping. Our products and solutions are underpinned by
extensive scientific research into the recipient's immune phenotype
and how that impacts on acute rejection, chronic injury and
ultimately failure of the transplant. These immuno-profile
signatures also inform clinicians as to the optimal strategy for
immunosuppressive and other therapies for the most successful
treatment to ensure graft acceptance with the least amount of side
effects.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFZGMNNLZGMZM
(END) Dow Jones Newswires
July 20, 2021 02:00 ET (06:00 GMT)
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024